ArticleAnnals of clinical and translational neurology2026
Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFacioscapulohumeral dystrophy type 1 (FSHD1) shows clinical heterogeneity that is only partly explained by D4Z4 repeat unit (RU) size. Although immune and inflammatory mechanisms may contribute to disease variability, the prevalence and clinical impact of autoimmune diseases in FSHD remain unclear. We investigated the spectrum of autoimmune comorbidities in FSHD1 and their relationship with D4Z4 repeat size, clinical phenotype, and disease severity.
methodsWe retrospectively analyzed 299 genetically confirmed FSHD1 patients followed at a national neuromuscular reference center. Clinical severity was assessed using the FSHD score and Comprehensive Clinical Evaluation Form classification. Demographic, genetic, and clinical features were compared according to autoimmune disease status. Multivariable linear regression assessed the independent association between autoimmune disease and FSHD severity, adjusting for age, sex, disease duration, D4Z4 RU number, and clinical phenotype.
resultsEighty-two patients (27.4%) had at least one autoimmune disease, totaling 96 autoimmune conditions. Several autoimmune diseases were markedly overrepresented compared with published population estimates. Patients with autoimmune disease had larger D4Z4 repeat arrays (7.18 ± 1.82 vs. 6.53 ± 1.81 RU, p = 0.002) but higher FSHD severity scores (7.98 ± 3.65 vs. 6.56 ± 3.51, p = 0.003). Autoimmune comorbidities were enriched in patients carrying 7-10 D4Z4 RU. In multivariable analysis, autoimmune disease remained independently associated with greater FSHD severity (β = 2.12, 95% CI 1.47-2.76, p < 0.0001).
conclusionsAutoimmune diseases are frequent in FSHD1 and independently associated with greater severity despite larger D4Z4 repeat arrays, supporting immune-related mechanisms as potential modifiers of FSHD1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.